Research & Clinical Trials
Concerning COVID-19 Only
All the advancements in preventing and treating COVID-19 are due to the brave volunteers who entered clinical trials for vaccines, monoclonal antibodies for both treatment and prevention, and antivirals. Here you will find both the results of important trials giving us the information needed to best navigate the pandemic and information about appropriate open trials that offer access to new cutting-edge therapies.
ADDITIONAL READING
While measles is very contagious and can be severe in CLL, most are thought to be significantly protected by past infections or immunizations.
The COVID-19 mortality rate was lower in recently vaccinated cancer patients and the same was true for B-cell cancers, including those with CLL.
Nirmatrelvir-ritonavir (Paxlovid) reduced the risk of death among immunocompromised patients who were hospitalized with COVID-19.
Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.
Now there is a new trial (SUPERNOVA) of an updated mix of monoclonal antibodies that hopes to provide durable protection against present and future variants of concerns.
This is the first study to show that pre-exposure prophylaxis, (PReP), with a mix of a long acting intramuscular (IM) injection of anti-COVID-19 monoclonal antibodies (AZD7442) is not only protective, significantly, it is protective in a high-risk population where “more than 75% of participants had co-morbidities, which include conditions
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
